Toward Dicalaimer To Obviote A Double Docket No.								
Terminal Disclaimer To Obviate A Double Patenting Rejection Over A Prior Patent						Army140D		
DEC 28 2007 B								
Application No.	Filing	Date \3	Exa	nginer	Customer No.	Group Art Unit	Confirmation No.	
10/767,687	January	29, 2004	A AHEUTA	arianne P.		1647	8007	
Invention: BACTERIAL SUPERANTIGEN VACCINES								
		· •						
		i						
Owner of Record: United States Army Medical Research Institute of Infectious Diseases								
Owner of Record. Officed States Army Medical Research Institute of States Army Medical Research								
		:						
COMMISSIONER FOR PATENTS:								
The above-identified owner of record of a 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6.713,284. The owner hereby agrees that any patent so granted on the instant application shall								
disclaimer, of prior Patent No. 6.713,284. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors and/or assigns.								
In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 158 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.								
Check either box 1 or 2 below, if appropriate.								
1. So For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.								
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.								
2. The undersigned is an attorney of record.								
Elizati	eth A	nume	<u> </u>	Date	d: 11 Decem	nher 200	7	
ELIZABETH ARWINE								
Typed or Printed Name  Terminal disclaimer fee under 37 C.F.R. 1.20(d) included.								
PTO suggested wording for terminal disclaimer was unchanged.  Certification under 37 C.F.R. 3.73(b) is required if terminal disclaimer is signed by the assignee.								

PTO/SB/96 (04-07)

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number.

## BON ACT OF 1889, NO PERSONS AND THE PROPERTY OF THE PROPERTY O

DEC 2 8 7007

Applicant/Patent Owner: United States Army Medical Research Inst	titute of Infectious Diseases (USAMRIID)
Application No./Patent No.: 6,713,284	Filed/Issue Date: March 30, 2004
Entitled: Bacterial Superantigen Vaccines	
USAMRIID , a Governmen	
(Name of Assignee) (Type of Assignee)	e.g., corporation, partnership, university, government agency, etc.)
states that it is:	
1.  the assignee of the entire right, title, and interest; or	
2. an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is	%)
in the patent application/patent identified above by virtue of either:	
A. An assignment from the Inventor(s) of the patent application/patent idea  States Patent and Trademark Office at Reel	ntified above. The assignment was recorded in the United 0605 , or for which a copy thereof is attatched.
OR	
B. A chain of title from the inventor(s), of the patent application/patent idea	ntified above, to the current assignee as follows:
1. From: To:	
The document was recorded in the United States Patent and Trademark  Reel, Frame, or for which a cop	. Office at ly thereof is attached.
2. From: To:	
The document was recorded in the United States Patent and Trademark	Office at
Reel, Frame, or for which a cop	by thereof is attached.
3. From:	
The document was recorded in the United States Patent and Trademark Reel, Frame, or for which a cop	c Office at by thereof is attached.
Additional documents in the chain of title are listed on a supplemental	
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the cha concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.  [NOTE: A separate copy (i.e., a true copy of the original assignment documents accordance with 37 CFR Part 3, to record the assignment in the interval of the control of the	ment(s)) must be submitted to Assignment Division in
The undersigned (whose title is supplied below) is authorized to act on behalf of	
Elizabeth Fruine Signature	11 December, 2007 Date
() Signature	
Elizabeth Arwine	301-619-7808
Printed or Typed Name	Telephone number
Attorney for applicant	
Title	

This collection of Information is required by 37 CFR 3.73(b). The Information is required to obtain or retain a banefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patenta, P.O. Box 1450, Alexandria, VA 22313-1450.